Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced participation in the Chardan 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:45 pm ET. Executives including Jennifer Ziolkowski, Chief Financial Officer, and Joel Schneider, Chief Technology Officer, will engage in a virtual fireside chat. A live webcast will be accessible via the company's Events page and an archived replay will be available for approximately 30 days. Solid Biosciences is dedicated to developing therapies for Duchenne muscular dystrophy, focusing on correcting the underlying mutation with their lead candidate, SGT-001.

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology Officer and Cathryn Clary, Interim Chief Medical Officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 pm ET.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

What event will Solid Biosciences participate in on October 6, 2020?

Solid Biosciences will participate in the Chardan 4th Annual Genetic Medicines Conference.

Who will represent Solid Biosciences at the Genetic Medicines Conference?

Jennifer Ziolkowski, Joel Schneider, and Cathryn Clary will represent Solid Biosciences.

What time is Solid Biosciences' presentation at the conference?

The presentation will take place at 4:45 pm ET.

How can I watch Solid Biosciences' presentation from the conference?

You can watch the presentation live on the company's Events page or access the archived replay for 30 days.

What is Solid Biosciences focused on developing?

Solid Biosciences focuses on advancing therapies for Duchenne muscular dystrophy.

What is the lead therapy candidate of Solid Biosciences?

The lead therapy candidate is SGT-001, aimed at correcting the mutation causing Duchenne.